Rexahn Pharmaceuticals, Inc.,
a clinical stage biopharmaceutical company developing next generation
therapeutics for the treatment of cancer, announced today that
additional data supporting the Company's novel, investigational
anti-cancer therapeutic, Supinoxin™ (RX-5902), for the treatment of
triple negative breast cancer.
"The nonclinical data for Supinoxin - along with human pharmacokinetic
data from the ongoing Phase I study, provides valuable evidence from
which to best inform our selection of a recommended Phase II dose for
further evaluation of Supinoxin," said Dr. Ely Benaim, Chief Medical
Officer for Rexahn. "Collectively, these data and the unique mechanism
of action of Supinoxin, coupled with the high unmet medical need for new
therapeutic options for patients diagnosed with TNBC, support our
selection of TNBC as one of the initial indications for Supinoxin in the
upcoming proof-of-concept Phase Ib/IIa clinical trial."
No comments:
Post a Comment